Status:

COMPLETED

Mayo Acute Stroke Trial for Enhancing Recovery

Lead Sponsor:

Mayo Clinic

Conditions:

Ischemic Stroke

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study involves treating patients that have suffered an acute ischemic stroke with the medication donepezil (Aricept ®). The hypothesis is that taking donepezil (FDA-approved for the treatment of ...

Detailed Description

We hypothesize that donepezil (5 mg per day, titrated up to 10 mg per day as tolerated) will enhance recovery following stroke by improving attention, learning and memory thereby enhancing rehabilitat...

Eligibility Criteria

Inclusion

  • Definite or probable acute ischemic cerebrovascular syndrome (AICS), as defined by Kidwell et al (Stroke. 2003;34:2995-8).
  • Experimental treatment started within 24 hours of onset of symptoms.
  • Age ≥ 18 years.
  • Ability and willingness to return for follow-up visits.
  • Willingness of an available informant who knows the patient well to participate in informant-based questionnaires for the duration of the follow-up period.
  • Living in independent or semi-independent living situation before the stroke.
  • Fluent in English before the stroke.
  • Provides written informed consent.
  • Near visual acuity of at least 20/200 in at least one eye.
  • Auditory acuity of at least having the ability to detect finger rubbing in at least one ear.

Exclusion

  • Parkinson's disease or restless leg syndrome.
  • Partial or generalized seizures.
  • No acute decompensated heart failure
  • Routinely requiring daytime supplemental oxygen before the stroke; study participants on continuous positive air pressure (CPAP) for obstructive sleep apnea remain eligible.
  • Gastrointestinal or genitourinary surgery within 1 month of screening.
  • Gastrointestinal bleeding.
  • Syncope or symptomatic bradycardia.
  • Creatinine ≥ 3.5 mg/dL or requiring dialysis.
  • Peptic ulcer disease.
  • Asthma.
  • Tracheostomy or endotracheal intubation.
  • Taking donepezil or other acetylcholinesterase inhibitor at screening.

Key Trial Info

Start Date :

November 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2010

Estimated Enrollment :

33 Patients enrolled

Trial Details

Trial ID

NCT00805792

Start Date

November 1 2008

End Date

September 1 2010

Last Update

July 30 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mayo Clinic

Jacksonville, Florida, United States, 32224